20th Oct 2023 15:30
GSK plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Emma Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 0.005 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Diana Conrad | |||
b) | Position/status | Chief People Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 254.875 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | Senior Vice President and Group General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 449.521 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Sally Jackson | |||
b) | Position/status | SVP, Global Communications and CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 309.976 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dylan Jackson | |||
b) | Position/status | PCA of Sally Jackson (SVP, Global Communications and CEO Office) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 168.369 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Luke Miels | |||
b) | Position/status | Chief Commercial Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 5,369.964 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | David Redfern | |||
b) | Position/status | President Corporate Development | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 3,880.768 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Regis Simard | |||
b) | Position/status | President, Global Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 909.398 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Phil Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 1,113.475 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Kate Thomson | |||
b) | Position/status | PCA of Phil Thomson (President, Global Affairs) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 96.036 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Deborah Waterhouse | |||
b) | Position/status | CEO, ViiV Healthcare and President, Global Health, GSK | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 470.946 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Tony Wood | |||
b) | Position/status | Chief Scientific Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
| |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£15.0571 | 376.751 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Hal Barron | |||
b) | Position/status | Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$36.6136 | 1,456.140 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | James Ford | |||
b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$36.6136 | 283.149
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Shobie Ramakrishnan | |||
b) | Position/status | Chief Digital and Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GSK plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044
| |||
b) | Nature of the transaction | Acquisition of ADSs following the re-investment of dividends paid to shareholders on 12 October 2023 | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$36.6136 | 93.393
| ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2023-10-17 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
Related Shares:
Glaxosmithkline